Literature DB >> 7539282

Region-specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma.

S R Ritland1, V Ganju, R B Jenkins.   

Abstract

Allelic mutation on chromosome 19 has previously been reported as a frequent genetic event in human glial tumors. In an effort to localize specific regions of importance on this chromosome better, 13 highly polymorphic genetic markers distributed along the length of chromosome 19 were used for evaluation of loss of heterozygosity (LOH) and microsatellite instability in a total of 100 brain tumors, including 75 astrocytomas (55 grade 4; 7 grade 3; 5 grade 2; 6 grade 1; and 2 other), 17 oligodendrogliomas (1 grade 4; 5 grade 3; 10 grade 2; and 1 grade 1), and 8 mixed oligoastrocytomas (MOA) (3 grade 4; 2 grade 3; and 3 grade 2). No microsatellite expansion was observed in these glial tumors for any of the chromosome 19 loci examined. LOH for loci on chromosome 19 was detected in 23/74 informative astrocytomas (31%), 11/17 oligodendrogliomas (65%), and 3/8 MOA (38%). Partial deletion of chromosome 19 occurred more frequently (31/37 cases) than did loss of one whole copy of the chromosome, and a morphology-specific pattern of LOH was observed. In 12/14 (86%) instances of chromosome 19 deletion in oligodendrogliomas and MOA, the 19q arm showed LOH, whereas the 19p arm showed no loss for all informative loci. Conversely, in 17/23 (74%) instances of chromosome 19 deletion in astrocytomas, the 19p arm showed LOH, whereas the 19q arm showed no loss for one or more loci. Thus, loss of 19q and retention of 19p are strongly associated with oligodendroglioma and MOA, whereas loss of 19p and retention of distal 19q is associated with astrocytoma.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539282     DOI: 10.1002/gcc.2870120407

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  12 in total

1.  Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas.

Authors:  D D Chi; R E Merchant; R Rand; A J Conrad; D Garrison; R Turner; D L Morton; D S Hoon
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

2.  Reversible tumorigenesis induced by deficiency of vasodilator-stimulated phosphoprotein.

Authors:  K Liu; L Li; P E Nisson; C Gruber; J Jessee; S N Cohen
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

3.  Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter.

Authors:  H Fujisawa; M Kurrer; R M Reis; Y Yonekawa; P Kleihues; H Ohgaki
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

4.  Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization.

Authors:  S H Bigner; M R Matthews; B K Rasheed; R N Wiltshire; H S Friedman; A H Friedman; T T Stenzel; D M Dawes; R E McLendon; D D Bigner
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

5.  Frequent loss of heterozygosity at the 19p13.3 locus without LKB1/STK11 mutations in human carcinoma metastases to the brain.

Authors:  S B Sobottka; M Haase; G Fitze; M Hahn; H K Schackert; G Schackert
Journal:  J Neurooncol       Date:  2000-09       Impact factor: 4.130

Review 6.  Molecular pathogenesis of oligodendroglial tumors.

Authors:  Judith W M Jeuken; Andreas von Deimling; Pieter Wesseling
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

7.  Genomic instability in pituitary adenomas.

Authors:  Janusz Szymas; Karsten Schluens; Wlodzimierz Liebert; Iver Petersen
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

8.  Rig is a novel Ras-related protein and potential neural tumor suppressor.

Authors:  Chad A Ellis; Michele D Vos; Heather Howell; Teresa Vallecorsa; Daniel W Fults; Geoffrey J Clark
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-09       Impact factor: 11.205

9.  The level of MnSOD is directly correlated with grade of brain tumours of neuroepithelial origin.

Authors:  M Landriscina; F Remiddi; F Ria; B Palazzotti; M E De Leo; M Iacoangeli; R Rosselli; M Scerrati; T Galeotti
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

10.  Clinical significance of the reduced expression of G protein gamma 7 (GNG7) in oesophageal cancer.

Authors:  M Ohta; K Mimori; Y Fukuyoshi; Y Kita; K Motoyama; K Yamashita; H Ishii; H Inoue; M Mori
Journal:  Br J Cancer       Date:  2008-01-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.